#CMV used to be the bane of the transplanters’ existence. Perhaps not the ogre it once was. Our team led by Sanjay Singhabahu and Liz Herrity demonstrate our experience with Letermovir and its differential impact across ethnicities. #Tandem24 #bmtsm Princess Margaret Cancer Centre University Health Network

Liz Herrity Arjun D. Law Ivan Pasic @tomam04 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM look who are the reigning Tandem 24 ID jeopardy champions !! #Tandem24

Toronto is diverse in every aspect, including in our patient population. In this poster Liz Herrity explores the impact of ethnicity in transplant outcomes. The good news, all our patients do just as well. Still many challenges to overcome but a good start! #Tandem24 #bmtsm

@tomam04 presenting his proposal in the chronic leukemia working committee. ( Co-authored with Arjun D. Law ) #Tandem24

Big thank you to Hans Messner Allogeneic BMT Program, Acute Leukemia, and Complex Malignant Hematology Day Unit providers who contributed to the creation and revision of my slides. All your time and effort was so much appreciated. #Tandem24

We’ve had a great #Tandem24 so far! 3 CIBMTR Working Committee proposals presented ✅ presented by @tomam04 and Niranjan Khaire

6 Poster abstracts ✅ (Plus more with other groups or multi centre trials) Ivan Pasic Arjun D. Law Liz Herrity Ayman Sayyed

A phenomenal talk given by Liz Herrity on the mechanisms of Leukemia relapse after #BMT at the APP session

We have a few overachievers in our program who think nothing of giving a talk and going for a quick afternoon jog. Sources say that other team members can be found obtaining er.. “liquid refreshments” while Ivan Pasic and Liz Herrity are off exercising. #priorities

#Tandem24 at 1.30 PM CAT today with Jeanne M Palmer Sumi Vasu Reshma Ramlal Co on education led spotlight session on rare yet consequential complications challenges and opportunities

Last #Tandem24 photo featuring far left to right: Arjun D. Law, Sanjay, Ivan Pasic, and me!

Microbiota and CAR-T cells interactions presented by Florent Malard as part of the ICTC meeting, brought to you by IACH ictclive.cme-congresses.com/program/ MaaT Pharma GutMicrobiota Health Gut Microbiota for Health NW Microbiome World of Microbiome Microbiome News

ICYMI: Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights onlinelibrary.wiley.com/doi/10.1111/bj… #leusm

Maintenance treatment was safe, with low rates of infections and chronic GVHD, and minimal impact on T-cell immune reconstitution. ow.ly/NAUY50QHhfz #clinicaltrialsandobservations #transplantation

Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs ow.ly/yvSE50QHhBH #systematicreview #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia

#mpnsm - How do you assess response to blast reduction therapy in AP/BP MPN; Princess Margaret Experience - Outcomes of intensive and non-intensive blast-reduction strategies in AP/BP MPN sciencedirect.com/science/articl…

Finally out! Pre-transplant blinatumomab improves outcomes in B-cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation - Journal of Transplantation and Cellular Therapy. astctjournal.org/article/S2666-…

Novel therapies that reduce both length of hospitalization after HCT and complication rates may significantly reduce allo-HCT costs. ow.ly/NCFU50QMVTU #healthservicesandoutcomes

Shared-Care in Complex Malignant Hematology: An Integrative Review Using the RE-AIM Evaluation Framework mdpi.com/2956722 via Current Oncology Bloomberg Nursing Princess Margaret Cancer Centre

🍀 Study finds no significant ethnic and racial disparities in post-allogeneic HCT outcomes, but age, comorbidity index & donor type vary. The rise of PTCy continues to reshape transplant equity. mdpi.com/2072-6694/17/4… by Elizabeth Herrity et al. #HCTResearch #HealthEquity